Rheumatoid arthritis (RA) is an autoimmune disease with chronic inflammation in the synovium of the joint tissue^[@R1]--[@R3]^. This inflammation leads to joint destruction, disability and shortened life span^[@R4]^. Defining key cellular subsets and their activation states in the inflamed tissue is a critical step to define new therapeutic targets for RA. CD4^+^ T cell^[@R5],[@R6]^ B cells^[@R7]^, monocytes^[@R8],[@R9]^, and fibroblasts^[@R10],[@R11]^ have established relevance to RA pathogenesis. Here, we use single cell technologies to view all of these cell types simultaneously across a large collection of samples from inflamed joints. We believe a global single-cell portrait of how different cell types work together would advance our understanding of therapeutics.

Application of transcriptomic and cellular profiling technologies to whole synovial tissue has already identified specific cell populations associated with RA^[@R3],[@R12]--[@R14]^. However, most studies have focused on a pre-selected cell type, surveyed whole tissues rather than disaggregated cells, or used only a single technology platform. The latest advances in single-cell technologies offer an opportunity to identify disease-associated cell subsets in human tissues at high resolution in an unbiased fashion^[@R15]--[@R17]^. These technologies have already been used to discover roles for T peripheral helper (Tph) cells^[@R18]^ and HLA-DR^+^CD27^−^ cytotoxic T cells^[@R19]^ in RA pathogenesis. Studies using scRNA-seq have defined myeloid cell heterogeneity in human blood^[@R20]^ and identified overabundance of PDPN^+^CD34^−^THY1^+^ (THY1, also known as CD90) fibroblasts in RA synovial tissue^[@R15],[@R21]^.

To generate high-dimensional multi-modal single-cell data from synovial tissue samples collected across a collaborative network of research sites, we developed a robust pipeline^[@R22]^ in the Accelerating Medicines Partnership Rheumatoid Arthritis and Lupus (AMP RA/SLE) consortium. We collected and disaggregated tissue samples from patients with RA and osteoarthritis (OA), and then subjected constituent cells to scRNA-seq, sorted-population bulk RNA-seq, mass cytometry, and flow cytometry. We developed a unique computational strategy based on canonical correlation analysis (CCA) to integrate multi-modal transcriptomic and proteomic profiles at a single cell level. A unified analysis of single cells across data modalities can precisely define contributions of specific cell subsets to pathways relevant to RA and chronic inflammation.

RESULTS {#S1}
=======

Generation of parallel mass cytometric and transcriptomic data from synovial tissue {#S2}
-----------------------------------------------------------------------------------

In phase 1 of AMP RA/SLE, we recruited 36 patients with RA that met the 1987 American College of Rheumatology (ACR) classification criteria and 15 patients with OA from 10 clinical sites over 16 months ([Supplementary Table 1](#SD3){ref-type="supplementary-material"}) and obtained synovial tissues from ultrasound-guided biopsies or joint replacements ([Methods](#S12){ref-type="sec"}, [Fig. 1a](#F1){ref-type="fig"}). We required that all tissue samples included had synovial lining documented by histology. Synovial tissue disaggregation yielded an abundance of viable cells for downstream analyses (362,190 +/− 7,687 (mean +/− SEM) cells per tissue). We used our validated strategy for cell sorting^[@R22]^ ([Fig. 1a](#F1){ref-type="fig"}) to isolate B cells (CD45^+^CD3^−^CD19^+^), T cells (CD45^+^CD3^+^), monocytes (CD45^+^CD14^+^), and stromal fibroblasts (CD45^−^CD31^−^PDPN^+^) ([Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}). We applied bulk RNA-seq to all four sorted subsets for all 51 samples. For samples with sufficient cell yield ([Methods](#S12){ref-type="sec"}), we also measured single-cell protein expression using a 34-marker mass cytometry panel (n=26, [Supplementary Table 2](#SD3){ref-type="supplementary-material"}**)**, and single-cell RNA expression in sorted cell populations (n=21, [Fig. 1b](#F1){ref-type="fig"}).

Summary of computational data integration strategy to define cell populations {#S3}
-----------------------------------------------------------------------------

To confidently define RA-associated cell populations, we integrated multiple data modalities ([Fig. 1b](#F1){ref-type="fig"}, [c](#F1){ref-type="fig"}). We use bulk RNA-seq data as the reference point because it was available for all of the donors and most of the cell types, it had the highest dimensionality and least sensitive to technical artifacts ([Fig. 1b](#F1){ref-type="fig"}).

Integrating scRNA-seq with bulk RNA-seq data ensures robust discovery of cell populations. Here, we used CCA to find linear combinations of bulk RNA-seq samples and scRNA-seq cells ([Fig. 1c](#F1){ref-type="fig"}, [d](#F1){ref-type="fig"}) to create gene expression profiles that were maximally correlated. These linear combinations captured sources of shared variation between the two datasets and allowed us to identify individual cell populations that drive variation in the bulk RNA-seq data. We analyzed the scRNA-seq data by using the canonical variate coefficients for each cell to compute a nearest neighbor network, identifying clusters with a community detection algorithm, and evaluating the separation between clusters with Silhouette analysis ([Methods](#S12){ref-type="sec"}, [Supplementary Fig. 2b](#SD1){ref-type="supplementary-material"}).

We identified cell clusters in mass cytometry data with density-based clustering^[@R23]^. Next, we used CCA to identify linear combinations of bulk RNA-seq genes and mass cytometry cluster abundances that maximize correlation across patients. These canonical variates offer a way to visualize genes and mass cytometry clusters together. We then queried this CCA result with the best marker genes from scRNA-seq to establish a relationship between each scRNA-seq cluster and each mass cytometry cluster ([Methods](#S12){ref-type="sec"}). We also used CCA to associate bulk gene expression in each sample with proportions of cells in different flow cytometry gates.

Flow cytometry features define a set of RA synovia that are leukocyte-rich {#S4}
--------------------------------------------------------------------------

Histology of RA synovial tissues revealed heterogeneous tissue composition with variable lymphocyte and monocyte infiltration ([Fig. 2a](#F2){ref-type="fig"},[b](#F2){ref-type="fig"}, [Supplementary Fig. 2c](#SD1){ref-type="supplementary-material"},[d](#SD1){ref-type="supplementary-material"}). This heterogeneity was expected, because variation in tissue immune cell infiltration reflects local disease activity in the source joint. Consequently, we employed a data-driven approach to separate samples based on flow cytometry of lymphocyte and monocyte infiltration in each tissue sample ([Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"},[c](#SD1){ref-type="supplementary-material"}). We calculated a multivariate normal distribution of these parameters based on OA samples as a reference, and for each RA sample we calculated the Mahalanobis distance from OA^[@R24]^. We defined the maximum OA distance (4.5) as the threshold for defining leukocyte-rich RA (\>4.5, n=19) or leukocyte-poor RA (\<4.5, n=17) samples ([Methods](#S12){ref-type="sec"}, [Supplementary Fig. 1d](#SD1){ref-type="supplementary-material"}). Whereas leukocyte-rich RA tissues had significant infiltration of synovial T cells and B cells, leukocyte-poor RA tissues had cellular compositions more similar to OA ([Fig. 2c](#F2){ref-type="fig"}). Synovial monocyte abundances were similar between RA and OA ([Fig. 2c](#F2){ref-type="fig"}).

To test if our classification indicates inflammation, we assessed tissue histology and assigned each sample a Krenn inflammation score^[@R25]^. Samples we classified as leukocyte-rich RA had a significantly higher Krenn inflammation score than leukocyte-poor RA or OA ([Fig. 2d](#F2){ref-type="fig"}). In contrast, synovial lining membrane hyperplasia was not significantly different between leukocyte-rich RA, leukocyte-poor RA, and OA samples ([Fig. 2d](#F2){ref-type="fig"}). We observed significant correlation between synovial leukocyte infiltration measured by flow cytometry and the histological Krenn inflammation score ([Fig. 2e](#F2){ref-type="fig"}). Mass cytometry in 26 synovial tissues was consistent with flow cytometry and histology. OA and leukocyte-poor RA samples were characterized by high abundance of fibroblasts and endothelial cells; while leukocyte-rich RA tissues were characterized by high abundance of CD4 T, CD8 T, and B cells ([Fig. 2f](#F2){ref-type="fig"}, [Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"}).

Single-cell RNA-seq analysis reveals distinct cell subpopulations {#S5}
-----------------------------------------------------------------

Next, we analyzed 5,265 scRNA-seq profiles passing quality control ([Methods](#S12){ref-type="sec"}), including 1,142 B cells, 1,844 fibroblasts, 750 monocytes, and 1,529 T cells. We used canonical variates (from CCA with bulk RNA-seq) to define 18 cell clusters that were independent of donor (n=21) and technical plate (n=24) effects ([Fig. 3a](#F3){ref-type="fig"}--b[b](#F3){ref-type="fig"}, [Supplementary Fig. 2c](#SD1){ref-type="supplementary-material"}, [Supplementary 4a](#SD1){ref-type="supplementary-material"}). In contrast, conventional PCA-based clustering led to clusters that were confounded by batch effects ([Supplementary Fig. 4b](#SD1){ref-type="supplementary-material"}). All of the clusters in the PCA-based clustering, excluding clusters confounded by batch, were identified in CCA-based clustering. Next, we compared expression values between cells in the cluster and all other cells to select cluster marker genes ([Methods](#S12){ref-type="sec"}, [Supplementary Table 4](#SD4){ref-type="supplementary-material"}). For selected genes, we show expression values in each cell positioned in a t-distributed Stochastic Neighbor Embedding (tSNE^[@R26]^) ([Fig. 3c](#F3){ref-type="fig"}--[f](#F3){ref-type="fig"}). Among fibroblasts, we identified four putative subpopulations ([Fig. 3c](#F3){ref-type="fig"}): *CD34*^+^ sublining fibroblasts (SC-F1), *HLA-DRA*^hi^ sublining fibroblasts (SC-F2), *DKK3*^+^ sublining fibroblasts (SC-F3), and *CD55*^+^ lining fibroblasts (SC-F4). In monocytes ([Fig. 3d](#F3){ref-type="fig"}), we identified *IL1B*^+^ pro-inflammatory monocytes (SC-M1), *NUPR1*^+^ monocytes (SC-M2), *C1QA*^+^ monocytes (SC-M3), and interferon (IFN) activated monocytes (SC-M4). In T cells ([Fig. 3e](#F3){ref-type="fig"}), we identified three CD4^+^ clusters: *CCR7*^+^ T cells (SC-T1), *FOXP3*^+^ regulatory T cells (T~reg~ cells) (SC-T2), and *PDCD1*^+^ Tph and T follicular helper (Tfh) (SC-T3); and three CD8^+^ clusters: *GZMK*^+^ T cells (SC-T4), *GNLY*^+^*GZMB*^+^ cytotoxic lymphocytes (CTLs) (SC-T5), and *GZMK*^+^*GZMB*^+^ T cells (SC-T6). Within B cells ([Fig. 3f](#F3){ref-type="fig"}), we identified four cell clusters, including naive *IGHD*^+^*CD27*^−^ (SC-B1) and *IGHG3*^+^*CD27*^+^ memory B cells (SC-B2). We identified an autoimmune-associated B cells (ABCs) cluster (SC-B3) with high expression of *ITGAX* (also known as *CD11c*) and a plasmablast cluster (SC-B4) with high expression of immunoglobulin genes *and XBP1*, a transcription factor for plasma cell differentiation^[@R27]^.

We assessed protein fluorescence measurements of typical cell type markers, which were consistent with our identified scRNA-seq clusters ([Supplementary Fig. 2e](#SD1){ref-type="supplementary-material"}). Cell density quantified from 10 histology samples was correlated with the lymphocyte flow cytometric cell yields, suggesting that samples with the most single cell measurements are those with the best yields and the most inflammation ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}).

Distinct synovial fibroblasts defined by cytokine activation and MHC II expression {#S6}
----------------------------------------------------------------------------------

To identify the fibroblast subpopulations overabundant in leukocyte-rich RA synovia, we selected marker genes for each cluster and assessed their expression levels in bulk RNA-seq from sorted fibroblasts (CD45^−^PDPN^+^) from RA and OA patients. For example, genes associated with *HLA-DRA*^hi^ (SC-F2) fibroblasts were more highly expressed in bulk RNA-seq samples from leukocyte-rich RA than OA (*t*-test p\<1×10^−3^ for *HLA-DRA*, *IFI30*, and *IL6*) ([Fig. 4a](#F4){ref-type="fig"}). Since the expression profile of a bulk tissue sample is an aggregate of the expression profiles of its constituent cell populations, this result suggests expansion of *HLA-DRA*^*hi*^ (SC-F2) fibroblasts in RA tissues. Genes associated with *CD55*^+^ fibroblasts (SC-F4) were significantly more highly expressed in bulk RNA-seq samples from OA than leukocyte-rich RA (*t*-test p\<1×10^−3^ for *HBEGF*, *CLIC5*, *HTRA4*, and *DNASE1L3*) ([Fig. 4a](#F4){ref-type="fig"}). *CD55*^+^ fibroblasts (SC-F4) were the most transcriptionally distinct subset from the three *THY1*^+^ clusters (SC-F1--3), including the highest expression of lubricin (*PRG4*), suggesting that these cells represent synovial lining fibroblasts and *THY1*^*+*^ fibroblasts (SC-F1--3) represent sublining ([Fig. 4a](#F4){ref-type="fig"}). Next, we use the averaged expression level of the best marker genes for each scRNA-seq cluster (AUC\>0.7) and tested for differential expression in bulk RNA-seq fibroblast samples from leukocyte-rich RA and OA synovia. The gene averages for *HLA-DRA*^hi^ sublining fibroblasts (SC-F2) and *CD34*^+^ sublining fibroblasts (SC-F1) were higher in leukocyte-rich RA compared to OA (*t*-test p=2×10^−6^ and p=2×10^−3^, respectively), while the gene averages for *CD55*^+^ lining fibroblasts (SC-F4) were higher in OA than leukocyte-rich RA (*t*-test p=5×10^−7^) ([Fig. 4b](#F4){ref-type="fig"}).

Consistent with the role of synovial fibroblasts in matrix remodeling, the sublining fibroblast subsets (SC-F1--3) expressed genes encoding extracellular matrix constituents ([Fig. 4c](#F4){ref-type="fig"}). *HLA-DRA*^hi^ sublining fibroblasts (SC-F2) expressed genes related to MHC class II presentation and the interferon gamma-mediated signaling pathway (*IFI30*) ([Fig. 4a](#F4){ref-type="fig"},[c](#F4){ref-type="fig"}), suggesting upregulation of MHC class II in response to interferon-gamma signaling in these cells. We identified a novel sublining fibroblast subtype (SC-F3) that is characterized by high expression of *DKK3*, *CADM1* and *COL8A2* ([Fig. 4a](#F4){ref-type="fig"}).

To independently confirm the presence of four fibroblast subpopulations discovered by scRNA-seq, we analyzed CD45^−^PDPN^+^ cells in mass cytometry data, and found eight putative cell clusters with differential protein levels of THY1, HLA-DR, CD34, and Cadherin-11 without obvious batch effects ([Fig. 4d](#F4){ref-type="fig"}--[g](#F4){ref-type="fig"}, [Supplementary Fig. 3b](#SD1){ref-type="supplementary-material"}). CCA revealed that greater abundance of THY1^+^CD34^−^HLA-DR^hi^ fibroblasts measured by mass cytometry is associated with higher expression of *IL6*, *CXCL12*, and *HLA-DRA* in bulk RNA-seq of the same samples, suggesting these cells are in an active cytokine-producing state ([Fig. 4h](#F4){ref-type="fig"}). CCA allowed us to place mass cytometry clusters in the same space as bulk RNA-seq genes, so we could query the positions of scRNA-seq genes within this space to find the correspondence between scRNA-seq clusters and mass cytometry clusters ([Fig. 4i](#F4){ref-type="fig"}, [Methods](#S12){ref-type="sec"}). We found *HLA-DRA*^hi^ sublining fibroblasts (SC-F2) correspond to THY1^+^CD34^−^HLA-DR^hi^ fibroblasts (z-score=2.8), and *CD34*^+^ sublining fibroblasts (SC-F1) correspond to THY1^+^CD34^+^HLA-DR^lo^ fibroblasts (z-score=2.7) ([Table 1](#T1){ref-type="table"}). Consistent with differential expression analysis of bulk RNA-seq, we found that THY1^+^CD34^−^HLA-DR^hi^ cells in the mass cytometry data were overabundant in leukocyte-rich RA relative to leukocyte-poor RA and OA controls (36% versus 2% of fibroblasts, MASC OR = 33.8 (95% CI: 11.7--113.1), one-sided MASC p=1.9×10^−5^) ([Table 1](#T1){ref-type="table"}).

To validate that the protein surface markers from mass cytometry were capturing the same transcriptional populations from scRNA-seq, we isolated fibroblasts from 10 synovial tissue samples based on surface protein levels of THY1 and HLA-DR and applied bulk RNA-seq ([Supplementary Fig. 6a](#SD1){ref-type="supplementary-material"}). We trained a linear discriminant analysis (LDA) classifier on fibroblast scRNA-seq data and used it to determine the most similar scRNA-seq cluster for each bulk RNA-seq sample. The sorted THY1^+^HLA-DR^+^ fibroblast population was similar to *THY1*^+^*HLA-DRA*^hi^ (SC-F2) and the THY1^−^ HLA-DR^−^ population was similar to *THY1*^−^ (SC-F4) ([Supplementary Fig. 7a](#SD1){ref-type="supplementary-material"}--[d](#SD1){ref-type="supplementary-material"}). Genes upregulated in the sorted THY1^+^HLA-DR^+^ fibroblasts included the interleukin *IL6* and the chemokine *CXCL12*, consistent with the scRNA-seq data.

Activation states define heterogeneity among synovial monocytes {#S7}
---------------------------------------------------------------

We identified four transcriptionally distinct monocyte subsets in the scRNA-seq data: *IL1B*^+^ pro-inflammatory monocytes (SC-M1), *NUPR1*^+^ monocytes (SC-M2), *C1QA*^+^ monocytes (SC-M3) and IFN-activated *SPP1*^+^ monocytes (SC-M4) ([Fig. 5a](#F5){ref-type="fig"}). In bulk RNA-seq monocyte samples from leukocyte-rich RA and OA donors, we found that genes associated with *IL1B*^+^ monocytes (SC-M1), including *NR4A2*, *HBEGF*, *PLAUR* and the IFN-activated gene *IFITM3* were significantly upregulated in leukocyte-rich RA samples (*t*-test p\<1×10^−4^). In contrast, marker genes associated with *NUPR1*^+^ monocytes (SC-M2) were downregulated in leukocyte-rich RA relative to OA ([Fig. 5a](#F5){ref-type="fig"}). Next, we took the average of the top marker genes (AUC\>0.7) for each monocyte scRNA-seq subset and tested for differential expression of these averages in the bulk RA versus OA RNA-seq data. This analysis suggests that leukocyte-rich RA synovia have a greater abundance of *IL1B*^+^ monocytes (*t*-test p=6×10^−5^) and IFN-activated monocytes (*t*-test p=6×10^−3^), but lower abundance of *NUPR1*^+^ monocytes (*t*-test p=2×10^−5^) ([Fig. 5b](#F5){ref-type="fig"}). These data suggest that cytokine activation drives expansion of unique monocyte populations in active RA synovia.

With GSEA, we tested MSigDB immunologic gene sets and found *IL1B*^*+*^ monocytes (SC-M1) have relatively high expression levels of genes defining the LPS response in monocytes and macrophages ([Fig. 5b](#F5){ref-type="fig"}). This suggests *IL1B*^*+*^ monocytes (SC-M1) are similar to TLR-activated IL-1-producing pro-inflammatory monocytes. Among Gene Ontology gene sets, we found *SPP1*^+^ monocytes (SC-M4) express genes induced by type I and II IFN ([Supplementary Fig. 8a](#SD1){ref-type="supplementary-material"}), including *IFITM3* and *IFI6* ([Fig. 5a](#F5){ref-type="fig"}). The transcriptional profiles of monocytes in SC-M2 and SC-M3 do not align with known activation states, possibly indicating that these clusters represent cell phenotypes tailored to the unique homeostatic needs of the synovium. Immunofluorescence staining confirmed the presence of CD14 and IL-1β positive cells in 6 tissue samples, consistent with an enrichment of the *IL1B*^+^ pro-inflammatory monocytes (SC-M1) phenotype in RA synovium ([Fig. 5d](#F5){ref-type="fig"}, [Supplementary Fig. 9a](#SD1){ref-type="supplementary-material"},[b](#SD1){ref-type="supplementary-material"}).

In the mass cytometry data, we identified five CD14^+^ monocyte clusters ([Fig. 5e](#F5){ref-type="fig"}--[h](#F5){ref-type="fig"}, [Supplementary Fig. 3c](#SD1){ref-type="supplementary-material"}). Using CCA to integrate mass cytometry and bulk RNA-seq data, we found that samples with a greater abundance of CD11c^+^CCR2^+^ and CD11c^+^CD38^+^ using mass cytometry also had a higher expression of *IFITM3*, *PLAUR*, *CD38*, and *HLA* genes ([Fig. 5i](#F5){ref-type="fig"}). This was consistent with a correspondence between the CD11c^+^CD38^+^ mass cytometry cluster and the activated monocyte scRNA-seq cluster *IL1B*^+^ (SC-M1) and *SPP1*^+^ (SC-M4) (z-score=2.3 and 2.3, respectively) ([Fig. 5j](#F5){ref-type="fig"}, [Table 1](#T1){ref-type="table"}). Supporting this finding, we confirmed that CD11c^+^CD38^+^ monocytes are significantly expanded in leukocyte-rich RA (OR = 7.8 (95% CI: 3.6--17.2), one-sided MASC p=6.7×10^−5^) ([Table 1](#T1){ref-type="table"}). Conversely, *NUPR1*^+^ monocytes (SC-M2) correspond to CD11c^−^ monocytes in mass cytometry and are inversely correlated with inflammatory monocyte populations (z-score=2.7) ([Fig. 5j](#F5){ref-type="fig"}, [Table 1](#T1){ref-type="table"}).

To confirm that putative populations from mass cytometry correspond to those identified by scRNA-seq clusters, we sorted CD14^+^ monocytes from 4 synovial tissue samples using CD11c and CD38 protein markers and assayed them with RNA-seq ([Supplementary Fig. 6c](#SD1){ref-type="supplementary-material"}). Importantly, we found that CD14^+^ synovial cells had high expression of both CD11c and CD38 particularly in the RA samples. The CD14^+^CD11c^+++^CD38^+++^ and CD14^+^CD11c^+^CD38^−^ sorted cells were consistent with *IL1B*^+^ pro-inflammatory (SC-M1) and *NUPR1*^+^ (SC-M2) cells, respectively ([Supplementary Fig. 7e](#SD1){ref-type="supplementary-material"}--[h](#SD1){ref-type="supplementary-material"}). These data, alongside the mass cytometry data, support the findings of greater abundance of *IL1B*^+^ pro-inflammatory (SC-M1) monocytes and lower abundance of *NUPR1*^+^ (SC-M2) monocytes in leukocyte-rich RA samples.

Heterogeneity in synovial CD4 and CD8 T cells defined by effector functions {#S8}
---------------------------------------------------------------------------

We found three CD4^+^ and three CD8^+^ T cell subsets in the scRNA-seq data ([Fig. 6a](#F6){ref-type="fig"}). *CCR7*^*+*^ T cells (SC-T1) expressed genes in the MSigDB immunologic gene set for central memory T cells ([Fig. 6a](#F6){ref-type="fig"}, [c](#F6){ref-type="fig"}). The two other CD4^+^ populations, *FOXP3*^+^ T~reg~ cells and *PDCD1*^+^ Tph and Tfh cells, were marked by high expression of *FOXP3* (SC-T2) and C*XCL13* (SC-T3) by examining differentially expressed genes between these two clusters^[@R18]^ ([Supplementary Fig. 8c](#SD1){ref-type="supplementary-material"}). *CXCL13*, a chemokine expressed by Tph cells, was upregulated in bulk-sorted T cells (CD45^+^CD14^−^CD3^+^) from leukocyte-rich RA compared to OA (*t*-test p=1.2×10^−4^) ([Fig. 6a](#F6){ref-type="fig"}). We found that the average of marker genes for Tph and Tfh cells (SC-T3) (AUC\>0.7) was higher in leukocyte-rich RA than OA samples (*t*-test p=0.01) ([Fig. 6b](#F6){ref-type="fig"}), suggesting greater abundance of Tph and activated T cells in RA than OA. We identified three CD8 T cell subsets characterized by distinct expression patterns of effector molecules *GZMK, GZMB, GZMA* and *GNLY* ([Fig. 6a](#F6){ref-type="fig"}). We defined these populations as *GZMK*^+^ (SC-T4), *GNLY*^+^*GZMB*^+^ cytotoxic T lymphocytes (CTLs) (SC-T5), and *GZMK*^+^*GZMB*^+^ T cells (SC-T6). *GZMK*^+^*GZMB*^+^ T cells (SC-T6) also expressed *HLA-DPA1* and *HLA-DRB1*, and other genes suggestive of an effector phenotype ([Fig. 6a](#F6){ref-type="fig"},[c](#F6){ref-type="fig"}).

To confirm these findings, we applied intracellular staining to tissues from RA samples and RNA-seq to sorted CD8 T cells. Intracellular staining of GZMK and GZMB proteins in disaggregated tissue samples from patients with RA revealed that the majority of CD8 T cells in synovial tissue express GZMK ([Supplementary Fig. 10a](#SD1){ref-type="supplementary-material"}). Furthermore, we found that most HLA-DR^+^ CD8 T cells express both GZMB and GZMK by intracellular protein staining ([Supplementary Fig. 10b](#SD1){ref-type="supplementary-material"}). In a comparison of 7 synovial tissue samples, CD8 T cells had higher proportion of IFNγ^+^ cells than CD4 T cells from the same sample ([Supplementary Fig. 10c](#SD1){ref-type="supplementary-material"},[d](#SD1){ref-type="supplementary-material"}). We also applied immunofluorescence to 6 synovial tissue samples and found that IFNγ^+^CD3^+^CD8^+^ T cells were more frequent in RA than OA ([Fig. 6d](#F6){ref-type="fig"}, [Supplementary Fig. 9c](#SD1){ref-type="supplementary-material"},[d](#SD1){ref-type="supplementary-material"}). Overall, these results closely mirror the findings from the scRNA-seq clusters.

Using mass cytometry, we identified nine putative T cell clusters among the synovial T cells (CD45^+^CD14^−^CD3^+^) ([Fig. 6e](#F6){ref-type="fig"}--[h](#F6){ref-type="fig"}, [Supplementary Fig. 3d](#SD1){ref-type="supplementary-material"}). By integrating bulk RNA-seq with mass cytometry cluster abundances, we found that higher gene expression of *CXCL13* and inhibitory receptors *TIGIT* and *CTLA4* was associated with greater abundance of the CD4^+^PD-1^+^ICOS^+^ mass cytometry cluster. Greater abundance of CD8^+^ PD-1^−^HLA-DR^+^ cells was associated with greater expression of *IFNG* ([Fig. 6i](#F6){ref-type="fig"}). We found correspondence between Tph and Tfh cells (SC-T3) and CD4^+^PD-1^+^ICOS^+^ T cells (z-score = 3.4). CD8^+^ subsets including *GZMK*^+^*GZMB*^+^ (SC-T6), CTLs (SC-T5), and *GZMK*^+^ (SC-T4) tracked with CD8^+^PD-1^−^HLA-DR^+^ T cells by mass cytometry ([Fig. 6j](#F6){ref-type="fig"}, [Table 1](#T1){ref-type="table"}). In addition, CD4^+^PD-1^+^ICOS^+^ cells were significantly overabundant in leukocyte-rich RA (MASC OR = 3 (95% CI: 1.7--5.2), one-sided MASC p=2.7×10^−4^) ([Table 1](#T1){ref-type="table"}).

Autoimmune-associated B cells expanded in RA synovium by single-cell RNA-seq {#S9}
----------------------------------------------------------------------------

We identified four synovial B cell clusters with scRNA-seq: naive B cells (SC-B1), memory B cells (SC-B2), *ITGAX*^+^ ABC cells (SC-B3), and plasmablasts (SC-B4) ([Fig. 7a](#F7){ref-type="fig"}). GSEA with Gene Ontology pathways suggested that SC-B1, SC-B2, and SC-B3 clusters represent activated B cells ([Supplementary Fig. 8b](#SD1){ref-type="supplementary-material"}). GSEA with MSigDB immunological gene sets revealed that SC-B1 cells express naive B cell genes, while SC-B2 and SC-B3 cells express IgM and IgG memory B cell genes ([Fig. 7b](#F7){ref-type="fig"}). SC-B3 cells express high levels of *ITGAX* and *TBX21 (T-bet)*, which are markers of autoimmunity-associated B cells ([Fig. 3f](#F3){ref-type="fig"} and [Fig. 7a](#F7){ref-type="fig"})^[@R28],[@R29]^, as well as markers of recently activated B cells including *ACTB*^[@R30]^. High expression of *AICDA* is consistent with the recently reported transcriptomic analysis of CD11c^+^ B cells from SLE peripheral blood^[@R31]^. Interferon stimulated genes (*GBP1* and *ISG15*) are also expressed in ABCs (SC-B3) and upregulated in leukocyte-rich RA ([Fig. 7a](#F7){ref-type="fig"}). While ABCs (SC-B3) constitute a relatively small proportion of all B cells, they are almost exclusively derived from two patients with leukocyte-rich RA ([Fig. 3b](#F3){ref-type="fig"}). To confirm the presence of ABCs in human tissues, we applied immunofluorescence staining to 6 synovial tissue samples. RA synovium had increased numbers of CD20^+^T-bet^+^ CD11c^+^ B cells compared to OA synovium. Specifically, we observed ABC cells in tissue sections from the same inflamed tissue samples that had a high proportion of ABCs by scRNA-seq analysis ([Fig. 7c](#F7){ref-type="fig"}, [Supplementary Fig. 9e](#SD1){ref-type="supplementary-material"}, [f](#SD1){ref-type="supplementary-material"}).

We identified 10 putative B cell clusters in the mass cytometry data (CD45^+^CD3^−^CD14^−^CD19^+^) ([Fig. 7d](#F7){ref-type="fig"}--[g](#F7){ref-type="fig"}, [Supplementary Fig. 3e](#SD1){ref-type="supplementary-material"}). CCA analysis showed that samples with higher gene expression of *CD38*, *MZB1*, and plasma cell differentiation factor *XBP1* had greater abundance of CD38^++^CD20^−^IgM^−^IgD^−^ plasmablasts ([Fig. 7h](#F7){ref-type="fig"}). Plasmablasts (SC-B4) corresponded with CD38^++^CD20^−^IgM^−^IgD^−^ B cells (z-score=2.7) ([Fig. 7i](#F7){ref-type="fig"}, [Table 1](#T1){ref-type="table"}). ABCs (SC-B3) corresponded with the IgM^−^ IgD^−^ HLA-DR^++^ CD20^+^ CD11c^+^ mass cytometry cluster (z-score=1.6), which is significantly overabundant in leukocyte-rich RA (OR = 5.7 (95% CI: 1.8--22.3), one-sided MASC p=2.7×10^−3^) ([Fig. 7i](#F7){ref-type="fig"}, [Table 1](#T1){ref-type="table"}). Mass cytometry analysis further identified three putative subsets within CD11c^+^ cells: IgM^−^IgD^−^HLA-DR^++^CD20^+^CD11c^+^, CD38^+^HLA-DR^++^CD20^−^CD11c^+^, and IgM^+^IgD^+^CD11c^+^, which is suggestive of additional heterogeneity within ABCs.

To demonstrate that CD19^+^CD11c^+^ cells by surface protein markers correspond to SC-B3 (ABCs), we flow-sorted CD19^+^CD11c^+^ cells from an independent cohort of 6 RA synovial samples and applied RNA-seq ([Supplementary Fig. 6b](#SD1){ref-type="supplementary-material"}). We show that these RNA-seq profiles are most consistent with ABC cells ([Supplementary Fig. 7i](#SD1){ref-type="supplementary-material"}--[k](#SD1){ref-type="supplementary-material"}). In these sorted samples, we found more putative marker genes (e.g. *ZEB2* and *CIITA*) and interferon-induced genes (*IFITM3* and *IFI27*) for the ABC population ([Supplementary Fig. 7l](#SD1){ref-type="supplementary-material"}).

Inflammatory pathways and effector modules revealed by global single cell profiling {#S10}
-----------------------------------------------------------------------------------

We used bulk and single cell transcriptomes of sorted synovial cells to examine pathologic molecular signal pathways. First, principal component analysis (PCA) on post-QC OA and RA bulk RNA-seq samples ([Supplementary Fig. 11a](#SD1){ref-type="supplementary-material"},[b](#SD1){ref-type="supplementary-material"}) showed that cell type accounted for most of the data variance. Each cell type expressed specific marker genes, *PDGFRA* for fibroblasts, *C1QA* for monocytes, *CD3D* for T cells, and *CD19* for B cells ([Supplementary Fig. 11c](#SD1){ref-type="supplementary-material"}). Within each cell type, PCA showed that leukocyte-rich RA samples separated from OA and leukocyte-poor RA samples ([Supplementary Fig. 11d](#SD1){ref-type="supplementary-material"}--[g](#SD1){ref-type="supplementary-material"}). Differential gene expression analysis between leukocyte-rich RA and OA (FC\>2 and FDR\<0.01) revealed genes upregulated in leukocyte-rich RA tissues: 173 in fibroblasts, 159 in monocytes, 10 in T cells, and 5 in B cells. To define the pathways relevant to leukocyte-rich RA, we used GSEA weighted by gene effect sizes on Gene Ontology pathways and identified type I interferon response and inflammatory response (monocytes and fibroblasts) ([Supplementary Fig. 11h](#SD1){ref-type="supplementary-material"}--[i](#SD1){ref-type="supplementary-material"}), Fc receptor signaling (monocytes), NF-kappa B signaling (fibroblasts), and interferon gamma (T cells) ([Fig. 8a](#F8){ref-type="fig"}). Leukocyte-rich RA samples had significantly higher expression of some genes in fibroblasts and monocytes: inflammatory response genes (*PTGS2, PTGER3*, and *ICAM1*), interferon response genes (*IFIT2, RSAD2, STAT1*, and *XAF1*), and chemokine or cytokine genes (*CCL2* and *CXCL9*) ([Fig. 8b](#F8){ref-type="fig"}), consistent with a coordinated chemotactic response to interferon activation. T cells had upregulation of interferon regulatory factors (IRFs), including *IRF7* and *IRF9*, and monocytes had upregulation of *IRF7*, *IRF8* and *IRF9*. Taken together, pathway analysis suggests crosstalk between immune and stromal cells in leukocyte-rich RA synovia. Inflammatory response genes upregulated in leukocyte-rich RA had comparable expression levels between leukocyte-poor RA and OA synovial cells ([Fig. 8b](#F8){ref-type="fig"})

Next, we asked whether inflammatory cytokines upregulated in leukocyte-rich RA are driven by global upregulation within a single synovial cell type, or specific upregulation within a discrete cell subset defined by scRNA-seq. Whereas *TNF* was produced at a high level by multiple monocyte, B cell and T cell populations; *IL6* expression was restricted to *HLA-DRA*^hi^ sublining fibroblasts (SC-F2) and a subset of B cells (SC-B1) ([Fig. 8c](#F8){ref-type="fig"}); CD8 T cells, rather than CD4 T cells, were the dominant source of *IFNG* transcription in leukocyte-rich synovia.

We also observed cell subset-specific responses to inflammatory pathways. Toll-like receptor signaling pathway was enriched in B cells and monocytes in leukocyte-rich RA tissues ([Fig. 8a](#F8){ref-type="fig"}). At the single cell level, we observed that *TLR10* was only expressed by activated B cells, indicating that *TLR10* has a functional role within the B cell lineage. In contrast, *TLR8* was elevated in all RA monocyte subsets. The hematopoietic cell-specific transcription factor *IRF8* was expressed in a significant fraction of monocytes and B cells that cooperatively regulate differentiation of monocytes and activated B cells in RA synovium. *SLAMF7* is highly expressed by pro-inflammatory monocytes (SC-M1), IFN-activated monocytes (SC-M4), CD8 T cells, and plasmablasts (SC-B4).

Furthermore, mass cytometry analysis across all identified cell clusters revealed that leukocyte-rich RA patients show high cell abundances of HLA-DR^hi^ fibroblast populations, Tph cells, CD11c^+^CD14^+^ monocytes, and CD11c^+^ B cell populations ([Supplementary Fig. 3f](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#S11}
==========

Using multi-model, high-dimensional synovial tissue data we defined stromal and immune cell populations overabundant in RA and described their transcriptional contributions to essential inflammatory pathways. Recognizing the considerable variation in disease duration and activity, treatment types, and joint histology scores^[@R32]^, we elected to use a molecular parameter, based on percent leukocytes of the total cellularity, to classify our samples at the local tissue level. We note that differences in leukocyte enrichment of joint replacement samples and biopsy samples were best explained by leukocyte infiltration and not by the histological scores ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}, [Supplementary Fig. 11d--g](#SD1){ref-type="supplementary-material"}).

This study and a previous study^[@R33]^ have highlighted sublining fibroblasts as a potential therapeutic target in RA. Sublining fibroblasts are a major source of pro-inflammatory cytokines such as *IL6* ([Fig. 4](#F4){ref-type="fig"}), and a specific subset of sublining fibroblasts expressing MHC II (SC-F2, *THY1*^*+*^*CD34*^*-*^*HLA-DR*^*hi*^) was \>15 fold expanded in RA tissues. Further studies are needed to define molecular mechanisms that regulate sublining fibroblast expansion in RA. T cells, B cells, and monocyte proportions track with expression of individual fibroblast genes ([Supplementary Fig. 11j](#SD1){ref-type="supplementary-material"}). We found *DNASE1L3*, a gene whose loss of function is associated with RA^[@R34]^ and systemic lupus erythematosus^[@R35]^ to be highly expressed in *CD55*^+^ lining fibroblasts (SC-F4) ([Fig. 4a](#F4){ref-type="fig"}). We identified a novel fibroblast subset (SC-F3) with high expression of *DKK3*+ ([Fig. 4](#F4){ref-type="fig"}), encoding Dickkopf3, a protein upregulated in OA that prevents cartilage degradation in vitro^[@R36]^.

Transcriptional heterogeneity in the synovial monocytes indicated that distinct RA-enriched subsets are driven by inflammatory cytokines and interferons ([Fig. 5](#F5){ref-type="fig"}). This suggests monocytes may be differentially polarized by unique cytokine combinations in local microenvironments. These newly identified inflammatory phenotypes align with RA therapeutic targets, including anti-TNF therapies and interferon pathway JAK kinase inhibitors^[@R37]^. The *NUPR1*^+^ (SC-M2) monocytes were inversely correlated with tissue inflammation, and expressed high levels of monocyte tissue remodeling factors such as *MERTK* ([Fig. 5](#F5){ref-type="fig"})^[@R38]^. Alternatively, *NUPR1*^+^ markers such as osteoactivin (*GPNMB*) and cathepsin K (*CTSK*) may indicate a subset of osteoclast progenitors that control bone remodeling ([Fig. 5](#F5){ref-type="fig"})^[@R37],[@R39]^. Furthermore, spatial studies---particularly focused on lining versus sublining, perivascular and lymphocyte aggregate-associated monocytes---will help understand the functional roles of these subsets.

Single cell classification of T cell subsets in RA synovium demonstrated CD4^+^ T cell heterogeneity that is consistent with distinction between the homing capacity and effector functions of these subsets. Consistent with previous studies, we observed expansion of *PDCD1*^+^*CD4*^+^ Tph cells (SC-T3) within leukocyte-rich RA. We also found CD8 T cell subsets (SC-T4--6) characterized by a distinct granzyme expression pattern ([Fig. 6a](#F6){ref-type="fig"}). A larger study may be better powered to differentiate the relative expansion of individual subpopulations.

A critical unmet need in RA is identifying therapeutic targets for patients failing to respond to disease-modifying antirheumatic drugs (DMARDs)^[@R41]^. We observed upregulation of chemokines (*CXCL8*, *CXCL9*, and *CXCL13*), cytokines (*IFNG* and *IL15*^[@R42],[@R43]^), and surface receptors (*PDGFRB* and *SLAMF7*) in distinct immune and stromal cell populations, suggesting potential novel targets. This study was enabled by advances in the statistical integration of single-cell data and our recent work optimizing robust methodologies for disaggregation of synovial tissue^[@R22]^.

We developed advanced strategies to integrate multiple molecular datasets by modulating technical artifact from single cell technologies^[@R44]^, while emphasizing biological signals. CCA has been successfully employed in other contexts to integrate high-dimensional biological data^[@R45],[@R46]^. Our CCA-based strategy analyzed scRNA-seq data using canonical variates that capture variance that are present in both single-cell and bulk RNA-seq data. The shared variances likely represent biological trends, and not technical factors that would likely be uncorrelated in these two independent datasets. We further confirmed that the identified scRNA-seq clusters are well correlated with the bulk RNA-seq data and also the mass cytometry data ([Supplementary Fig. 12](#SD1){ref-type="supplementary-material"}, [13](#SD1){ref-type="supplementary-material"}).

The two single cell modalities used in this study, mass cytometry and scRNA-seq, complement each other. Single-cell RNA-seq captures expression of thousands of genes, but at the cost of sparse data^[@R47]^. Mass cytometry captures hundreds of thousands of individual cells, but measures a limited number (\~40)^[@R48]^ of pre-selected markers. However, since markers are backed with decades of experimental experience they can be effective at defining cellular heterogeneity^[@R49]^. To make the analysis consistent, we gated mass cytometry cells on the same markers upon which the scRNA-seq was gated. Combining mass cytometry with the extended dimensionality of scRNA-seq enables quantification of well-established cell populations and discovery of novel cell states, such as the CD8 T cell states noted here. As an ongoing AMP phase 2 study, we are examining larger numbers of ungated cell populations from \~100 synovial tissue patients with RA by capturing mRNA and protein expression simultaneously^[@R50]^ with detailed clinical data and ultrasound score evaluation of synovitis. We anticipate that this larger study will enable us to not only discover additional subpopulations, but to better define their link to clinical sub-phenotypes.

It is essential to interrogate the tissue infiltration of diseases other than RA, including SLE, type I diabetes, psoriasis, multiple sclerosis and other organ targeting conditions. Application of multiple single-cell technologies together can help define key novel populations, thereby providing new insights about etiology and potential therapies.

Methods {#S12}
=======

Study design and patient recruitment {#S13}
------------------------------------

The study was performed in accordance with protocols approved by the institutional review board. A multicenter, cross-sectional study of individuals undergoing elective surgical procedures and a prospective observational study of synovial biopsy specimens from patients with RA ≥ age 18, with at least one inflamed joint, recruited from 10 contributing sites in the network. Synovial tissues were obtained from joint replacement procedures or ultrasound-guided biopsies, followed by cryopreservation in cryopreservation media Cryostor CS10 (Sigma-Aldrich) and transit to a central technology site.

Histological assessment of synovial tissue and quality control {#S14}
--------------------------------------------------------------

Synovial tissue quality and grading of synovitis were evaluated in formalin-fixed, paraffin-embedded sections by histologic analysis (H and E staining). Specimens were identified as synovium by the presence of a lining layer or by characteristic histologic features of synovium, including the presence of loose fibrovascular or fatty tissue lacking a lining layer. Samples consisting of dense fibrous tissue, joint capsule or other tissues were determined not to be synovium. For each histological and molecular analysis, we generated pooled data from 6--8 separate fragments from different sites in the same joint. Thus, this should be representative of the whole tissue and mitigate much of the biopsy site-to-site variability. Krenn lining scores (0--3) and inflammation scores (0--3) for each tissue sample were determined independently by three pathologists^[@R25]^.

Tissue disaggregation for mass cytometry and RNA-sequencing {#S15}
-----------------------------------------------------------

For pipeline analysis, synovial tissue samples stored in cryovials were disaggregated into single cell suspension as describe. Briefly, synovial tissue fragments were separated mechanically and enzymatically in digestion buffer (Liberase TL (Sigma-Aldrich) 100 ug/mL and DNase I (New England Biolabs) 100 ug/ml in RPMI) in a 37°C water bath for 30 minutes. Single cell suspensions from disaggregated synovial tissues were assessed for cell quantity and cell viability by trypan Blue. For samples with more than 200,000 viable synovial cells, 50% of all synovial cells were allocated for analysis by mass cytometry and the remaining cells were allocated for RNA-seq. For samples with less than 200,000 viable synovial cells, all synovial cells were utilized for RNA-seq analysis.

Synovial cell sorting strategy for RNA sequencing {#S16}
-------------------------------------------------

Synovial T cells, B cells, monocytes, and fibroblasts were isolated from disaggregated synovial tissue, as described^[@R22]^. Briefly, disaggregated synovial cells were stained with antibodies against CD45 (HI30), CD90 (5E10), podoplanin (NZ1.3), CD3 (UCHT1), CD19 (HIB19), CD14 (M5E2), CD34 (4H11), CD4 (RPA-T4), CD8 (SK1), CD31 (WM59), CD27 (M-T271), CD235a (KC16), using human TruStain FcX in 1% BSA in Hepes-Buffered Saline (HBS,20 mM HEPES, 137 mM NaCl, 3mM Kcl, 1mM CaCl2) for 30 minutes. 1000 viable (PI-) T cells (CD45^+^, CD3^+^, CD14^−^), monocytes (CD45^+^, CD3^−^, CD14^+^), B cells (CD45^+^, CD3^−^, CD14^−^, CD19^+^), and synovial fibroblasts (CD45^−^, CD31^−^, PDPN^+^) were collected by fluorescence-activated cell sorting (BD FACSAria Fusion) directly in buffer RLT (Qiagen) for bulk RNA-seq. For single cell RNA-seq, live cells of each population were re-sorted into 384-well plates single cells with a maximum of 144 cells for each cell type, per patient sample.

Flow sorting strategy for bulk RNA-seq experimental validation {#S17}
--------------------------------------------------------------

For bulk RNA-seq validation experiments, RA and OA synovial tissue were disaggregated and synovial cells were stained with cell-type specific antibody panels. For each cell subset, up to 1000 cells were collected directly into buffer TCL (Qiagen). Antibody panels used to define cell subsets are fibroblasts: CD90 (5E10), podoplanin (NZ1.3), HLA-DR (G46--6); B cell subsets: HLA-DR (G46--6), CD11c (3.9), CD19 (SJ25C1), CD27 (M-T271), IgD (IA6--2), CD3 (UCHT1), CD14 (M5E2), CD38 (HIT2); Monocyte subsets: CD14-BV421 (M5E2), CD38-APC (HB-7), and CD11c-PECy7 (B-ly6). Immediately prior to sorting, DAPI or LIVE/DEAD viability dye was added to cell suspensions and cells were passed through a 100μm filter. Synovial cell subsets were sorted based on flow cytometry gating schema shown in [Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}. In all, we sorted THY1^−^ DR^−^ populations from 4 OA samples, THY1^+^DR^−^ population from 4 OA and 6 RA samples, and THY1^+^ DR^+^ population from 6 RA samples. For monocytes, we sorted CD14^+^CD11c^+++^CD38^+++^ population from 2 RA samples and CD14^+^CD11c^+^ CD38^−^ population from 2 OA samples. For B cells, we sorted CD11c^−^IgD^−^CD27^+^ population from 6 RA samples, CD11c^−^IgD^+^CD27^−^ population from 3 RA samples, CD19^+^CD11c^+^ population from 3 RA samples, and plasma cells from 3 RA samples.

To validate the identified single-cell populations using bulk RNA-seq, we fit an LDA (Linear Discriminant Analysis) classifier on the scRNA-seq cell clusters and then classified each flow sorted bulk RNA-seq sample. For each cell type, 1) we trained an LDA model on the scRNA-seq clusters with the top 500 marker genes for each cluster; 2) Next, we applied this LDA model to classify each sample of bulk sorted cells and estimated the maximum posterior probability for each sample. In summary, we tested if we could sort new cells from new, independent samples and see the same gene expression profiles in the new bulk samples as the original scRNA-seq samples.

Multicolor immunofluorescent staining of paraffin synovial tissue {#S18}
-----------------------------------------------------------------

Briefly, 5 mm thick formalin fixed paraffin sections were incubated in a 60°C oven to melt paraffin. Slides were quickly transferred to xylenes to completely dissolve the paraffin and after 5 minutes transferred to absolute ethanol. Slides were left in absolute ethanol for 5 minutes and then transferred to 95% ethanol. At the end of the 5 minutes immersion in 95% ethanol, slides were rinsed several times with distilled water and transfer to a plastic coplin jar filled with 1× DAKO retrieval solution (S1699, Dakocytomation). Antigens were unmasked by immersing of plastic coplin jar in boiling water for 30 minutes. Slides were let cool down for 10 minutes at room temperature and washed several times with distilled water. Non-specific binding was blocked with 5% normal donkey serum (017-000-121, Jackson ImmunoResearch Laboratories,) dissolved in PBS containing 0.1% Tween 20 and 0.1% Triton X-100. Without washing, blocking solution was removed from slides and combinations of primary antibodies were added to PBS containing 0.1% Tween 20 and 0.1% Triton X-100. Primary antibodies to detect IFNg^+^ T cells include goat anti-CD3 epsilon (clone M-20, Santa Cruz Biotechnology), mouse anti-human CD8 (clone 144B, GeneTex), and rabbit anti-human IFNg (Biorbyt, orb214082). To visualize ABC, we incubated slides with goat anti-human CD20 (LifeSpan Biosciences, LS-B11144), rabbit anti-Tbet (H-210, Santa Cruz Biotechnology) and biotinylated mouse anti-human CD11c (clone 118/A5, Thermo Fisher Scientific). To identify *IL1B*^+^ monocytes, we used a mixture of goat anti human CD14 (119--13402, RayBiotech) biotinylated rabbit anti-human IL1b (OABF00305-Biotin, Aviva Systems Biology) and mouse anti-human CD16 (clone DJ130c, LifeSpan Biosciences). Finally, slides were probed with rabbit monoclonal anti-human CD90 (2694--1, Epitomics), rat anti-human HLADR (cloneYE2/36 HLK, LifeSpan Biosciences) and mouse anti-human CD45 (clone F10-89-4, abcam) to detect fibroblasts, Class II expressing cells and hematopoietic cells, respectively. Slides with primary antibodies were incubated in a humid chamber at room temperature, overnight. Next morning, primary antibodies for triple T cell stain and for detecting ABC's were revealed with Alexa Fluor 568 donkey anti-goat IgG (A-11057, Thermo Fisher Scientific), Alexa Fluor 488 donkey anti-rabbit (771-546-152, Jackson ImmunoResearch Laboratories) and Alexa fluor 647 donkey anti-mouse (715-606-151, Jackson ImmunoResearch Laboratories). Primary antibodies in the stain for monocytes were revealed with Alexa Fluor 568 donkey anti-goat Ig G, Alexa fluor 488 streptavidin (S11223, Thermo Fisher Scientific) and Alexa Fluor 647 donkey anti-mouse Ig G. Primary antibodies in the stain for fibroblasts and hematopoietic cells were detected with Cy3 donkey anti-rabbit (711-166-152, Jackson ImmunoResearch Laboratories), Alexa Fluor 488 donkey anti-rat Ig G (A-21208, Thermo Fisher Scientific) and Alexa Fluor 647 donkey anti-mouse Ig G. After 2 hours of incubation, slides were washed and mounted with Vectashield mounting media with DAPI (H-1200, Vector Laboratories). Pictures were taken with an Axioplan Zeiss microscope and recorded with a Hamamatsu camera. Double immunofluorescence pictures were obtained by merging individual channels in NIH Image J software.

Estimation of number of cells by counting nuclei {#S19}
------------------------------------------------

To estimate number of cells, we counted number of nuclei in 5 random 200× fields that show synovial lining with Image J NIH software. Briefly, original color TIFF files were first transformed into 8-bit grayscale images. We use similar settings to adjust threshold in 8-bit images (Lower threshold level: 0, Upper threshold level: 60). Next, we used process: binary: watershed to separate nuclei. In the analyze icon, we select analyze particles and we use equal settings to count particles in our images (Size (pixel^2^): 50-infinity, circularity 0.00--1.00, Show: outlines) and we selected to display results. We visually confirmed that individual nuclei were outlined in the final image and calculate the average number of cells/200× field in individual samples.

Tissue samples classification based on leukocyte infiltration {#S20}
-------------------------------------------------------------

We classified RA tissue samples into leukocyte-poor RA and leukocyte-rich RA based on Mahalanobis distance from OA samples computed on leukocyte abundance measured by flow cytometry. We first took OA samples as a reference, and calculated a multivariate normal distribution of the percentages of live T cells, B cells, and monocytes. Here we used the mahalanobis function in R: data *x* = a matrix of all 51 samples by flow gates of T cells, B cells, and monocytes; center = mean of T cells, B cells, and monocytes for all OA samples; covariance = covariance of T cells, B cells, and monocytes for all OA samples. We calculated the square root to get Mahalanobis distance for each sample, $$mah = \sqrt{\left( {x - \mu} \right)\text{'}\Sigma^{- 1}\left( {x - \mu} \right)}.$$We then defined the maximum value of all OA samples (4.5) as a threshold to define 19 leukocyte-rich RA (\>4.5) and 17 leukocyte-poor RA (\<4.5) samples in our cohort ([Supplementary Fig. 1d](#SD1){ref-type="supplementary-material"}).

Bulk RNA-seq gene expression quantification {#S21}
-------------------------------------------

We sorted cells into the major immune and stromal cell populations: T cells, B cells, monocytes and synovial fibroblasts. We then performed RNA sequencing. Full-length cDNA and sequencing libraries were performed using Illumina Smart-eq2 protocol^[@R51]^. Libraries were sequenced on MiSeq from Illumina to generate 35 base paired-end reads. Reads were mapped to Ensembl version 83 transcripts using kallisto 0.42.4 and summed expression of all transcripts for each gene to get transcripts per million (TPM) for each gene.

Bulk RNA-seq quality control {#S22}
----------------------------

For quality control of bulk RNA-seq data, we began by defining *common genes* as the set of genes detected with at least 1 mapped fragment in 95% of the samples. Then, for each sample, we computed the percent of common genes detected in that sample. Low quality samples are those that have less than 99% of common genes detected, and these were discarded. We found that the low-quality samples also had low cell counts ([Supplementary Fig. 11a](#SD1){ref-type="supplementary-material"}). After discarding 25 low quality samples, we used 167 good quality samples, including 45 fibroblast samples, 46 monocyte samples, 47 T cell samples, and 29 B cell samples in all bulk RNA-seq analyses. Cell lineage markers, *PDGFRA*, *C1QA, CD3D*, and *CD19*, are expressed selectively by fibroblasts, monocytes, T cells, and B cells, respectively ([Supplementary Fig. 11c](#SD1){ref-type="supplementary-material"}).

Single-cell RNA-seq gene expression quantification {#S23}
--------------------------------------------------

Single-cell RNA-seq was performed using the CEL-Seq2 method^[@R47]^ with the following modifications. Single cells were sorted into 384-well plates containing 0.6 μL 1% NP-40 buffer in each well. Then, 0.6 μL dNTPs (10mM each; NEB) and 5 nl of barcoded reverse transcription primer (1 μg/μL) were added to each well along with 20 nL of ERCC spike-in (diluted 1:800,000). Reactions were incubated at 65°C for 5 min, and then moved immediately to ice. Reverse transcription reactions were carried out, as previously described (Hashimshony *et al*., 2016), and cDNA was purified using 0.8× volumes of Agencourt RNAClean XP beads (Beckman Coulter). *In vitro* transcription reactions (IVT) were performed, as described followed by EXO-SAP treatment. Amplified RNA (aRNA) was fragmented at 80°C for 3 min and purified using Agencourt RNAClean XP beads (Beckman Coulter). The purified aRNA was converted to cDNA using an anchored random primer and Illumina adaptor sequences were added by PCR. The final cDNA library was purified using Agencourt RNAClean XP beads (Beckman Coulter). Paired-end sequencing was performed on the HiSeq 2500 in High Output Run Mode with a 5% PhiX spike-in using 15 bases for Read 1, 6 bases for the Illumina barcode and 36 bases for Read 2. We mapped Read2 to human reference genome hg19 using STAR 2.5.2b, and removed samples with outlier performance using Picard. We quantified gene levels by counting UMIs (Unique Molecular Identifiers) and transforming the counts to Log~2~(CPM+1) (Counts Per Million).

Single-cell RNA-seq quality control {#S24}
-----------------------------------

For quality control of single-cell RNA-seq data, we filtered out molecules that are likely to be contamination between cells, and we used several metrics to exclude poor quality cells. We identified molecules that are likely to represent cell-to-cell cross-contamination as follows. Many single-cell RNA-seq library preparation protocols include pooling and amplification of cDNA molecules from a large number of cells. This can introduce cell-to-cell contamination. We found that molecules represented by a small number of reads are more likely to be contaminant molecules derived from other cells. We developed a simple algorithm to set a threshold for the minimum number of reads per molecule, and we ran it separately for each quadrant of 96 wells in each 384-well plate. We used 2 marker genes expected to be exclusively expressed in each of the 4 cell types: *PDGFRA* and *ISLR* for fibroblasts, *CD2* and *CD3D* for T cells, *CD79A* and *RALGPS2* for B cells, and *CD14* and *C1QA* for monocytes. We counted nonzero expression of these genes in the correct cell type as a true positive and nonzero expression in the incorrect cell type as a false positive. Then we tried each threshold for reads per molecule from 1--20 and chose the threshold that maximizes the ratio of true positive to false positive ([Supplementary Fig. 14](#SD1){ref-type="supplementary-material"}). This left us with 7,127 cells and 32,391 genes. Next, we discarded cells with fewer than 1,000 genes detected with at least one fragment. We also discarded cells that had more than 25% of molecules coming from mitochondrial genes. This left us with 5,265 cells. We discarded genes that had nonzero expression in fewer than 10 cells. We show all post-QC single cells based on the number of genes detected and percent of molecules from mitochondrial genes for each identified cluster ([Supplementary Fig. 15](#SD1){ref-type="supplementary-material"}).

Mass cytometry sample processing and quality control {#S25}
----------------------------------------------------

We collected 6 leukocyte-rich, 9 leukocyte-poor RA, and 11 OA samples for mass cytometry analysis, and processed the samples, as described previously^[@R22]^. Briefly, we analyzed samples on a Helios instrument (Fluidigm) after antibody staining and fixation ([Supplementary Table 2](#SD3){ref-type="supplementary-material"}). Mass cytometry data were normalized using EQ™ Four Element Calibration Beads (Fluidigm), as previously described^[@R52]^. Cells were first gated to live DNA+ cells prior to gating for specific cell populations using the following scheme: B cells (CD3^−^CD14^−^CD19^+^), fibroblasts (CD45^−^PDPN^+^), monocytes (CD3^−^CD14^+^), and T cells (CD3^+^CD14^−^). All biaxial gating was performed using FlowJo 10.0.7.

Integrative computational pipeline for scRNA-seq clustering {#S26}
-----------------------------------------------------------

We developed a graph-based unbiased clustering pipeline based on canonical correlation analysis to take advantage of the shared variation between single-cell RNA-seq and bulk RNA-seq. We used this computational pipeline to analyze single cells from each cell type. The overall flowchart is shown in [Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}. We describe the details of each step as follows: We first selected the highly variable genes such that the mean and standard deviation are in the top 80% of the density distributions from the single-cell RNA-seq matrix *C* (*g* genes by *m* cells, *c*~1*,...,m*~) and bulk RNA-seq matrix (*g* genes by *n* samples, *s*~1*,...,n*~), respectively. We focused on the highly variable genes detected in both scRNA-seq and bulk RNA-seq datasets.Based on the shared highly variable genes, we integrated single-cell RNA-seq with bulk RNA-seq by finding a linear projection of bulk samples and single cells such that the correlation between the genes are maximized using the CCA method^[@R53]^. CCA finds two vectors *a* and *b* that maximize the linear correlations *cor*(*CV*~*s*1~,*CV*~*c*1~) where $CV_{s1} = a_{1}s_{1} + a_{2}s_{2} + \ldots + a_{n}s_{n}$ and $CV_{c1} = b_{1}c_{1} + b_{2}c_{2} + \ldots + b_{m}c_{m}$. Each bulk sample *s*~*i*~ gets a coefficient *a*~*i*~ and each cell *c*~*i*~ gets a coefficient *b*~*i*~. The linear combination of all samples *s*~1,...,*n*~ arranges bulk genes along the canonical variate *CV*~*s*1~ and the linear combination of all cells *c*~1,...,*m*~ arranges single-cell genes along *CV*~*c*1~ CCA defines the coefficients *a*~1,...,*n*~ and *b*~1,...,*n*~ that arrange the genes from the two datasets in such a way that the correlation between *CV*~*s*1~ and *CV*~*c*1~ is maximized. After CCA finds the first pair of canonical variates, the next pair is computed on the residuals, and so on.We calculated the cell-to-cell similarity matrix using Euclidean distance on the top ten CCA canonical variates.We built up a K-nearest neighbors (KNN) graph based on the cell-to-cell similarity matrix (Euclidean distance) based on local ordinal embedding (LOE), a graph embedding method. We then converted the KNN neighbor relation matrix into an adjacency matrix using the graph.adjacency function from igraph R package;We clustered the cells using the Infomap algorithm for community detection by applying a cluster_infomap function from igraph R package to decompose the cell-to-cell adjacency matrix into major modules by minimizing a description of the information flow;We then constructed a low dimensional embedding using tSNE based on the cell-to-cell distance matrix using the following parameters: perplexity = 50 and theta = 0.5;We identified and prioritized significantly differentially expressed genes for each distinct cluster based on percent of non-zero expressing cells, AUC score^[@R54]^, and fold-change;For pathway analysis, we downloaded gene sets from Gene Ontology (GO) terms on April 2017^[@R55],[@R56]^. This included 9,797 GO terms and 15,693 genes. We also used the immunological signatures from 4872 hallmark gene sets from MSigDB^[@R57]^ to test enrichment of all the tested genes sorted by decreased AUC scores for each cluster by 10^5^ permutation tests^[@R55]^. We used the liger R package (<https://github.com/JEFworks/liger>) to do gene set enrichment analysis (GSEA). To identify the most reasonable and stable clusters, we ran this pipeline repeatedly while tuning the number of top canonical variates (4, 8, 12, 16, and 20) that were incorporated for the cell-to-cell similarity matrix, and the number of k (50, 100, 150, 200, 250, and 300) to build up the K-nearest neighbors' graph. We chose the clusters that yielded the greatest number of differentially expressed genes. We used Silhouette analysis^[@R58],[@R59]^ on the cell-to-cell Euclidean distance matrix to evaluate our clustering results ([Supplementary Fig. 2b](#SD1){ref-type="supplementary-material"}). For each cell, the silhouette width *s*(*i*) is defined as follows: $$s\left( \text{i} \right) = \frac{b\left( i \right) - a\left( i \right)}{\text{max}\left( {a\left( i \right),~b\left( i \right)} \right)},$$ where *a*(*i*) is the average dissimilarity between a cell and all the other cells in the same cluster and *b*(*i*) is the average distance between a cell and all cells in the nearest cluster to which the cell does not belong. The measure range is \[−1, 1\], where a value near 1 indicates a cell is far from neighboring clusters, a value near 0 indicates a cell is near a decision boundary, and a value near −1 indicates the cell is closer to a neighboring cluster than its own cluster.

Thus, for each pair of single-cell RNA-seq and bulk RNA-seq, we ran our pipeline on the shared samples that have both datasets for each cell type ([Figure 1b](#F1){ref-type="fig"}). For integrating fibroblast data, we used 45 bulk RNA-seq samples, 1,844 single cells and 7,016 shared highly variable genes; for integrating monocyte data, we used 47 bulk RNA-seq samples, 750 single cells and 7,016 shared highly variable genes; for integrating T cell data, we used 47 bulk RNA-seq samples, 1,716 single cells and 7,003 shared highly variable genes; for integrating B cell data, we used 29 bulk RNA-seq samples, 1,142 single cells and 7,023 shared highly variable genes.

Mass cytometry clustering {#S27}
-------------------------

We created mass cytometry datasets for analysis by concatenating cells from all individuals for each cell type. For donors with more than 1,000 cells, we randomly selected 1,000 cells to ensure that samples were equally represented. In this way, we created downsampled datasets of 25,161 fibroblasts from 23 patients, 15,298 monocytes from 26 patients, 19,985 T cells from 26 patients, and 8,179 B cells from 23 patients for analysis. We then applied the tSNE algorithm (Barnes-Hut implementation) to each dataset using the following parameters: perplexity = 30 and theta = 0.5. We used all markers except those used to gate each population in the SNE clustering. To identify high-dimensional populations, we used a modified version of DensVM^[@R23]^. DensVM performs kernel density estimation across the dimensionally reduced SNE map to build a training set, then assigns cells to clusters by their expression of all markers using an SVM classifier. We modified the DensVM code to increase the range of potential bandwidths searched during the density estimation step and to return the SVM model generated from the tSNE projection. We summarized the details of the clusters with proportion of cells from each disease cohort in [Supplementary Table 3](#SD3){ref-type="supplementary-material"}.

Disease association test of cell populations {#S28}
--------------------------------------------

We tested whether abundances of individual populations were altered in RA case samples compared to OA controls using two ways. First, we assessed whether marker genes (AUC \> 0.7, 20 \< n \< 100) characteristic of each scRNA-seq cluster were differentially expressed in the same direction in scRNA-seq and bulk RNA-seq datasets. Second, we applied MASC^[@R19]^, a single cell association method for testing whether case-control status influences the membership of single cells in any of multiple cellular subsets while accounting for technical confounds and biological variation. We specified donor identity and batch as random-effect covariates.

Integration of bulk RNA-seq with mass cytometry {#S29}
-----------------------------------------------

We used CCA to associate the abundances of mass cytometry clusters with gene expression in bulk RNA-seq. We started by selecting the samples that had both data types. The mass cytometry data matrix has samples and clusters, where the values represent proportions of cells from each sample in each cluster. The bulk RNA-seq data matrix has samples and genes, where the values represent proportions of gene abundance from each sample in each gene. CCA identifies canonical variates (a linear combination of bulk RNA-seq genes and a linear combination of mass cytometry cluster proportions) that maximize correlation of samples along each canonical variate. In other words, it tries to arrange samples from each dataset in a similar order along each canonical variate. We ran CCA separately for fibroblasts, monocytes, T cells, and B cells. For fibroblasts, we associated 2,299 genes with 8 mass cytometry clusters on 22 samples. For monocytes, we associated 2,161 genes with 5 mass cytometry clusters on 25 samples. For T cells, we associated 2,255 genes with 9 mass cytometry clusters on 26 samples. For B cells, we associated 22,95 genes with 10 mass cytometry clusters on 17 samples.

Finding correspondence between scRNA-seq clusters and mass cytometry clusters {#S30}
-----------------------------------------------------------------------------

1\) For each cell type, we ran CCA with mass cytometry clusters with bulk RNA-seq. Each gene is correlated with each canonical variate (CV). Also, each mass cytometry cluster is correlated with each CV. By visualizing these correlations, we can see the positions of bulk RNA-seq genes and mass cytometry clusters in the same space ([Figure 4h](#F4){ref-type="fig"}).

2\) We then associated single-cell RNA-seq clusters with mass cytometry clusters by projecting cluster markers (AUC \> 0.7) for each single-cell RNA-seq cluster in the CCA space acquired from step 1).

3\) We took the average across the cluster marker genes for each single-cell RNA-seq cluster for each CV and obtained an "average CV" matrix.

4\) Based on the "average CV" matrix, we computed Spearman correlation between the scRNA-seq average CV and the CV for mass cytometry clusters.

5\) Next, we generated a null distribution for the Spearman correlations by shuffling the scRNA-seq gene names and then repeating steps 2--4 10,000 times.

6\) For the 10,000 replicates of CCA matrix, we repeated from step 2 to step 5. Then, we counted how many times the correlation of each pair was greater than the observed value from step 4).
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7\) Finally, we converted the to a *permutation p* to a *z* − *score*.

Differential expression analysis with bulk RNA-seq {#S31}
--------------------------------------------------

We classified all the samples into OA, leukocyte-poor RA, and leukocyte-rich RA synovial tissues based on the quantitative analysis of T cells, B cells, and monocytes by flow cytometry. PCA on bulk RNA-seq samples showed separation of leukocyte-rich and leukocyte-poor RA on the first or second principal components. For differential analysis, we used the limma R package to identify significantly differentially expressed genes. We used the Benjamini-Hochberg method to estimate false discovery rate (FDR).

Identification of markers for distinct scRNA-seq clusters {#S32}
---------------------------------------------------------

Based on the single-cell RNA-seq clusters, we identified cluster marker genes by comparing the cells in one cluster with all other clusters from the same cell type, based on Log~2~(CPM+1). We prioritized cluster marker genes using three criteria: 1) percent of non-zero expressing cells \> 60%; 2) are under the receiver-operator curve (AUC)^[@R54]^ \> 0.7; and 3) fold-change (FC) \> 2.

Intracellular flow cytometry of synovial tissue T cell stimulation {#S33}
------------------------------------------------------------------

Disaggregated synovial tissue cells were incubated with Fixable Viability Dye (eBioscience) and Fc blocking antibodies (eBioscience) followed by staining for surface markers in Brilliant Stain Buffer (BD Bioscience). Cell were then fixed and permeabilized using an intracellular staining kit (eBioscience), followed by intracellular staining for granzymes or cytokines. Antibodies used in this study include anti-CD45 (clone HI30) from BD Biosciences; anti-CD3 (clone UCHT1), anti-CD8 (clone SK1), anti-CD14 (clone M5E2), anti-CD4 (clone RPA-T4), anti-HLA-DR (clone L243), anti-granzyme B (clone GB11), and anti-granzyme K (clone GM26E7) from Biolegend; and anti-IFNG (clone 4S.B3) and anti-TNF (clone MAb11) from eBioscience. Data were collected on a BD Fortessa flow cytometer and analyzed using FlowJo 10.5 software. Disaggregated synovial tissue cells were incubated with a cell stimulation cocktail containing PMA and ionomycin (eBioscience) in RPMI with 10% fetal calf serum (Gemini). After 15 minutes, brefeldin A (eBioscience) was added. The cells were incubated at 37C 5% CO~2~ for an additional 2 hours. The cells were then collected and stained for intracellular cytokines following the protocol above and the data was shown in [Supplementary Fig. 10](#SD1){ref-type="supplementary-material"}.

Statistics {#S34}
----------

Results are shown as mean with 95% confidence intervals. The statistics tests used were *t*-test and Kolmogorov-Smirnov test, unless otherwise stated, as described with one-sided or two-sided in the figure legends. Benjamini-Hochberg FDR \< 0.01 and Fold-change \> 2 were considered to be statistically significant when appropriate.

Supplementary Material {#SM1}
======================
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Reporting Summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data Availability

The single-cell RNA-seq data, bulk RNA-seq data, mass cytometry data, flow cytometry data, and the clinical and histological data this study are available at ImmPort (<https://www.immport.org/shared/study/SDY998> and <https://www.immport.org/shared/study/SDY999>, study accession codes SDY998 and SDY999). The raw single-cell RNA-seq and mass cytometry data are deposited in dbGAP (<https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001457.v1.p1>. The source code repository of the computational and statistical analysis is located at<https://github.com/immunogenomics/amp_phase1_ra>. Data can also be viewed on 3 different websites at <https://immunogenomics.io/ampra>, <https://immunogenomics.io/cellbrowser/>, and <https://portals.broadinstitute.org/single_cell/study/amp-phase-1>.
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![Overview of synovial tissue workflow and pairwise analysis of high-dimensional data. **a**. We acquired synovial tissue, disaggregated the cells, sorted them into four gates representing fibroblasts (CD45^−^CD31^−^PDPN^+^), monocytes (CD45^+^CD14^+^), T cells (CD45^+^CD3^+^), and B cells (CD45^+^CD3^−^CD19^+^). We profiled these cells with mass cytometry, flow cytometry, sorted low-input bulk RNA-seq, and single-cell RNA-seq. Here, we use Servier Medical Art by Servier for the joint picture. **b**. Presence and absence of five different data types for each tissue sample. **c**. Schematic of each dataset and the shared dimensions used to analyze each of the three pairs of datasets with canonical correlation analysis (CCA). **d**. CCA finds a common mapping for two datasets. For bulk RNA-seq and single-cell RNA-seq, we first find a common set of g genes present in both datasets. Each bulk sample s~i~ gets a coefficient a~i~ and each cell c~i~ gets a coefficient b~i~. The linear combination of all samples s~1...n~ arranges bulk genes along the canonical variate CV~s1~ and the linear combination of all cells c~1...m~ arranges single-cell genes along CV~c1~. CCA finds the coefficients a~1...n~ and b~1...m~ that arrange the genes from the two datasets in such a way that the correlation between CV~s1~ and CV~c1~ is maximized. After CCA finds the first pair of canonical variates, the next pair is computed on the residuals, and so on.](nihms-1524330-f0001){#F1}

![Distinct cellular composition in synovial tissue from OA, leukocyte-poor RA, and leukocyte-rich RA patients. **a**. Histological assessment of synovial tissue derived from OA (*n* = 15 independent tissue samples), leukocyte-poor RA (*n* = 17 independent tissue samples), and leukocyte-rich RA (*n* = 19 independent tissue samples). **b**. Cellular composition of major synovial cell types by flow cytometry. **c**. Synovial T cells, B cells, and monocytes by flow cytometry in samples from OA (*n* = 15), leukocyte-poor RA (*n* = 17), and leukocyte-rich RA (*n* = 19). Leukocyte-rich RA tissues were significantly higher infiltrated in synovial T cells (Student's one-sided t-test *P* = 4×10^−9^, t-value = 8.92, df = 22.27) compared to leukocyte-poor RA and OA. Leukocyte-rich RA tissues were significantly higher infiltrated in synovial B cells (Student's one-sided t-test *P* = 1×10^−3^, t-value = 3.50, df = 20.56) compared to leukocyte-poor RA and OA. Center value is mean. Statistical significance levels: \*\*\*\**P*\<1×10^−4^ and \*\*\**P*\<1×10^−3^. **d**. Quantitative histologic inflammatory scoring of both sublining cell layer and lining layer. Leukocyte-rich RA samples (*n* = 19) exhibited higher (Student's one-sided t-test *P* = 1×10^−3^, t-value = 3.21, df = 30.66) Krenn inflammation scores than leukocyte-poor RA (n=15) and OA tissues (*n* = 10) samples. Center value is mean. **e**. Correlation between leukocyte infiltration assessed by cytometry with histologic inflammation score (*n* = 44 biologically independent samples). Student's one-sided t-test *P* = 3×10^−09^, t-value = 7.15, df = 46.51. **f**. tSNE visualization of synovial cell types in OA, leukocyte-poor RA, and leukocyte-rich RA by mass cytometry density plot.](nihms-1524330-f0002){#F2}

![High-dimensional transcriptomic scRNA-seq clustering reveals distinct cell type subpopulations. **a**. 18 clusters across 5,265 cells from all cell types on a tSNE visualization. **b**. Cluster abundances across donors. **c**. Fibroblasts: three types of *THY1*^+^ sublining fibroblasts (SC-F1, SC-F2, and SC-F3) and *CD55*^+^ lining fibroblasts (SC-F4). **d**. Monocytes: two activated cell states of *IL1B*^+^ pro-inflammatory (SC-M1) and IFN-activated (SC-M4) monocytes. **e**. T cells: *CD4*^+^ subsets: SC-T1, SC-T2, SC-T3, and *CD8*^+^ subsets: SC-T4, SC-T5, and SC-T6. **f**. B cells: *HLA*^+^ (SC-B1, SC-B2, and SC-B3) and plasmablasts (SC-B4). The cluster colors in **c-f** are consistent with (**a**).](nihms-1524330-f0003){#F3}

![Distinct synovial fibroblast subsets defined by cytokine activation and MHC II expression. **a**. scRNA-seq analysis identified three sublining subsets, *CD34*^+^ (SC-F1), *HLA*^hi^ (SC-F2), and *DKK3*^+^ (SC-F3) and one lining subset (SC-F4). Differential analysis between leukocyte-rich RA (*n* = 16) and OA (*n* = 12) bulk RNA-seq fibroblast samples shows marker genes upregulated or downregulated in leukocyte-rich RA. Fold changes with 95% confidence interval (CI). **b**. By querying the leukocyte-rich RA (*n* = 16) and OA (*n* = 12) fibroblast bulk RNA-seq samples, scRNA-seq cluster *HLA-DRA*^hi^ (SC-F2) and *CD34*^+^ (SC-F1) fibroblasts are significantly overabundant (two-sided Student's t-test *P*=2×10^−6^, t-value=6.2, df = 23.91 and *P*=2×10^−3^, t-value = 3.20, df = 25.41, respectively) in leukocyte-rich RA relative to OA. Lining fibroblasts (SC-F4) are overabundant (two-sided Student's t-test *P*=5×10^−7^, t-value=−5.31, df =21.97) in OA samples. Fold changes with 95% CI. **c**. Pathway enrichment analysis for each cluster. Two-sided Kolmogorov-Smirnov test with 10^5^ permutations; Benjamini-Hochberg FDR is shown. **d-e**. Identified subpopulations from fibroblasts (*n* = 25,161) and disease status from 6 leukocyte-rich RA, 9 leukocyte-poor RA, and 8 OA by mass cytometry on the same gating with scRNA-seq. **f-g**. Normalized intensity of distinct protein markers shown in tSNE visualization and averaged for each cluster heatmap. **h**. CCA projections of mass cytometry clusters and bulk RNA-seq genes. First two canonical variates (CVs) separated genes upregulated in leukocyte-rich RA from genes upregulated in OA. *HLA*^*h*i^ genes are highly associated with THY1^+^CD34^−^HLA-DR^hi^ by mass cytometry. **i**. Integration of mass cytometry clusters with scRNA-seq clusters based on the top markers (AUC \> 0.7) for each scRNA-seq cluster using top 10 canonical variates in the low-dimensional CCA space. We computed the spearman correlation between each pair of scRNA-seq cluster and mass cytometry cluster in the CCA space and performed permutation test 10^4^ times. Z-score is calculated based on permutation p-value. We observed HLAhigh sublining fibroblasts by scRNA-seq are strongly correlated with THY1^+^CD34^−^HLA-DR^hi^ fibroblasts by mass cytometry.](nihms-1524330-f0004){#F4}

![Unique activation states define synovial monocytes heterogeneity. **a**. scRNA-seq analysis identified four subsets: *IL1B*^+^ pro-inflammatory monocytes (SC-M1), *NUPR1*^+^ monocytes (SC-M2) with a mixture of leukocyte-poor RA and OA cells, *C1QA*^+^ (SC-M3), and IFN-activated monocytes (SC-M4). Differential analysis by bulk RNA-seq on leukocyte-rich RA samples (*n* = 17) and OA samples (*n* = 13) revealed upregulation/downregulation of cluster marker genes. Effect sizes with 95% CI are given. **b**. By querying the bulk RNA-seq, we found scRNA-seq cluster *IL1B*^*+*^ pro-inflammatory monocytes (two-sided Student's t-test *P*=6×10^−5^, t-value=4.56, df =26.33) and IFN-activated monocytes (two-sided Student's t-test *P*=6×10^−3^, t-value=3.28, df =23.68) are upregulated in leukocyte-rich RA (*n* = 17) compared to OA (*n* = 13), while SC-M2 is depleted (two-sided Student's t-test *P*=2×10^−5^, t-value=−5.62, df=26.81) in leukocyte-rich RA. Error bars indicate mean and 95% CI. **c**. Pathway enrichment analysis indicates the potential pathways for each subset. Two-sided Kolmogorov-Smirnov test with 10^5^ times permutation was performed; Benjamini-Hochberg was used to control the FDR of multiple tests. The standard names for the immunological gene sets from up to bottom are: Genes down-regulated in neutrophils versus monocytes (GSE22886); Genes down-regulated in healthy myeloid cells versus SLE myeloid cells (GSE10325); Genes down-regulated in control microglia cells versus those 24 h after stimulation with IFNG (GSE1432); Genes down-regulated in unstimulated macrophage cells versus macrophage cells stimulated with LPS (GSE14769); Genes up-regulated monocytes treated with LPS versus monocytes treated with control IgG (GSE9988); Genes up-regulated in monocytes versus myeloid dendritic cells (mDC) (GSE29618); Genes up-regulated in monocytes versus plasmacytoid dendritic cells (pDC) (GSE29618). **d**. Detection of pro-inflammatory IL-1β in inflamed synovium by multicolor immunofluorescent staining with antibodies CD14 (red), IL-1β (green), and counterstained with DAPI (blue) identified CD14^+^IL-1β^+^ cells (white arrow). The experiment was repeated \> 5 times with staining of 6 independent leukocyte-rich RA samples with similar results. Image was acquired at 200 magnification. Scale bar is 50 μm. **e--f**. Identified subpopulations from monocytes (*n* = 15,298) and disease status from 6 leukocyte-rich RA, 9 leukocyte-poor RA, and 11 OA by mass cytometry on the same gating with scRNA-seq. **g-h**. Normalized intensity of distinct protein markers by tSNE visualization and averaged for each cluster in heatmap. **i**. Integration of identified mass cytometry clusters with bulk RNA-seq reveals genes that are associated with CD11c^+^CD38^+^ and CD11c^+^CCR2^+^, like IFITM3, CD38, HBEGF, ATF3, and HLA+ genes. **j**. Integration of mass cytometry clusters and scRNA-seq clusters revealed that CD11c+CD38+ by mass cytometry are significantly associated with *IL1B*^+^ pro-inflammatory (SC-M1) monocytes.](nihms-1524330-f0005){#F5}

![Synovial T cells display heterogeneous CD4 and CD8 T cell subpopulations in RA synovium. **a**. scRNA-seq analysis identified three CD4^+^ subsets: *CCR7*^+^ (SC-T1), T~reg~ cells (SC-T2), and Tph and Tfh (SC-T3); and three CD8^+^ subsets: *GZMK*^+^ (SC-T4), CTLs (SC-T5), and *GZMK*^+^*GZMB*^+^ (SC-T6). Differential expression analysis on leukocyte-rich RA (*n* = 18) comparing with OA (*n* = 13) on sorted T cell bulk RNA-seq samples revealed that *CXCL13* is most significantly enriched in leukocyte-rich RA compared to OA. Effect sizes with 95% CI are given. **b**. Disease association of scRNA-seq clusters by aggregating top markers (AUC\>0.7) by comparing leukocyte-rich RA (*n* = 18) with OA (*n* = 13) using bulk RNA-seq. Tph and Tfh cells (SC-T4) are upregulated (two-sided Student's t-test p=0.01, t-value=2.73, df =29.00) in leukocyte-rich RA. Error bars indicate mean and 95% CI. **c**. Pathway analysis based on immunologic gene set enrichment indicates the potential enriched T cell states pathways. Two-sided Kolmogorov-Smirnov test with 10^5^ times permutation was performed; Benjamini-Hochberg was used to control the FDR of multiple tests. The brief description of the standard names from up to bottom are: Genes up-regulated in CD4 high cells from thymus: Treg versus T conv (GSE42021); Genes up-regulated in comparison of effector CD8 T cells versus memory CD8 T cells (GOLDRATH); Genes down-regulated in comparison of effector memory T cells versus central memory T cells from peripheral blood mononuclear cells (PBMC) (GSE11057); Genes up-regulated in comparison of effective memory CD4 T cells versus Th1 cells (GSE3982); Genes up-regulated in comparison of T follicular helper (Tfh) cells versus Th17 cells (GSE11924). **d**. Detection of CD3^+^CD8^+^IFNγ^+^ (white arrow) in inflamed RA synovium by multicolor immunofluorescent staining with antibodies CD3 (green), CD8 (red), IFNγ (white), and counterstained with DAPI (blue). The experiment was repeated \> 5 times with staining of 6 independent leukocyte-rich RA samples with similar results. Image was acquired at 200 magnification. Scale bar is 50 μm. **e-f**. Identified subpopulations from T cells (*n* = 19,985) and disease status from 6 leukocyte-rich RA, 9 leukocyte-poor RA, and 11 OA by mass cytometry. **g-h**. Distinct patterns of protein markers by tSNE and heatmap that define these clusters. **i**. Integration of identified mass cytometry clusters with bulk RNA-seq using CCA reveals bulk genes that are associated with CD4^+^PD-1^+^ICOS^+^ and CD8^+^PD-1^−^HLA-DR^+^ by mass cytometry. **j**. Integration of mass cytometry clusters with scRNA-seq clusters on the top markers (AUC\>0.7) for each scRNA-seq cluster in the top 10 canonical variates. Z-score based on permutation test reveals that CD4^+^PD-1^+^ICOS^+^ and CD8^+^PD-1^+^HLA-DR^+^ by mass cytometry are highly associated with Tph and Tfh (SC-T3) by scRNA-seq; CD8^+^PD-1^−^HLA-DR^+^ T cells by mass cytometry are highly associated with CD8^+^ T cells (SC-T4, SC-T5, and SC-T6).](nihms-1524330-f0006){#F6}

![Synovial B cells display heterogeneous subpopulations in RA synovium. **a**. scRNA-seq analysis identified naive B cells (SC-B1), memory B cells (SC-B2), autoimmune-associated B cells (ABCs) (SC-B3), and plasmablasts (SC-B4). Differential expression analysis is given by comparing leukocyte-rich RA (*n* = 16) with OA (*n* = 7) using bulk RNA-seq B cell samples. Effect size with 95% CI are given. **b**. Pathway enrichment analysis using immunologic gene sets indicates the distinct enriched pathways for each scRNA-seq cluster. Two-sided Kolmogorov-Smirnov test with 10^5^ times permutation was performed; Benjamini-Hochberg was used to control the FDR of multiple tests. The standard names for the immunological gene sets from up to bottom are: Genes up-regulated in plasma cells versus memory B cells (GSE12366); Genes up-regulated in comparison of B cells versus plasmacytoid dendritic cells (pDC) (GSE29618); Genes up-regulated in B lymphocytes: naive versus plasmablasts (GSE42724); Genes up-regulated in B lymphocytes: human germinal center light zone versus dark zone (GSE38697); Genes up-regulated in comparison of memory IgM B cells versus plasma cells from bone marrow and blood (GSE22886); Genes up-regulated in comparison of memory IGG and IGA B cells versus plasma cells from bone marrow and blood (GSE22886). **c**. Detection of CD20^+^T-bet^+^CD11c^+^ (white arrow) in inflamed synovium by multicolor immunofluorescence. Immunofluorescent staining with antibodies CD20 (red), CD11c (white), T-bet (green), and counterstained with DAPI (blue). The experiment was repeated \> 5 times with staining of 6 independent leukocyte-rich RA samples with similar results. Image was acquired at 200 magnification. Scale bar is 50 μm. **d-e**. Identified subpopulations of B cells (*n* = 8,179) and disease status from 6 leukocyte-rich RA, 9 leukocyte-poor RA, and 8 OA by mass cytometry. **f-g**. Distinct expression patterns of protein markers by tSNE and averaged for each cluster in heatmap. **h**. Integrating mass cytometry clusters with bulk RNA-seq data using CCA shows that CD38^+^CD20^−^Ig^−^ (plasmablasts) population is highly associated with gene expression of plasma cells makers, like XBP1. **i**. Integration of mass cytometry clusters with scRNA-seq clusters suggested that CD38^++^CD20^−^IgM^+^HLA-DR^+^ and CD38^++^CD20^−^IgM^−^IgD^−^ are significantly associated with plasmablast (SC-B4); IgM^−^IgD^−^HLA-DR^++^CD20^+^CD11c^+^ B cells are associated with ABCs (SC-B3).](nihms-1524330-f0007){#F7}

![Transcriptomic profiling of synovial cells reveals upregulation of inflammatory pathways in RA synovium. **a**. Pathway enrichment using bulk RNA-seq identified shared and unique inflammatory response pathways for each cell type. Two-sided Kolmogorov-Smirnov test with 10^5^ permutations was performed on 18 leukocyte-rich RA, 17 leukocyte-poor RA, and 14 OA. **b**. Bulk RNA-seq profiling of genes obtained from the significantly enriched pathways from (**a**) shows the averaged gene expression from each group (18 leukocyte-rich RA, 17 leukocyte-poor RA, and 14 OA) normalized across all cell type samples. **c**. scRNA-seq profiling resolved that inflammatory cytokines/chemokines, interferon responsive, and inflammatory responsive genes were driven by a global upregulation within a synovial cell type or discrete cell states.](nihms-1524330-f0008){#F8}

###### 

Connection between cell populations determined by mass cytometry and scRNA-seq clusters and disease associations. Bold mass cytometry clusters are significantly enriched in leukocyte-rich RA (one-sided Benjamini-Hochberg FDR q value \< 0.05). Two significant digits are given to the one-sided F-tests conducted on nested models with MASC. 95% confidence interval (CI) for the odds ratio (OR) is given for each mass cytometry cluster. Where possible, we have identified the most similar scRNA-seq clusters for each cluster found by mass cytometry. The mass cytometry analysis is performed on downsampled datasets of 25,161 fibroblasts from 23 patients, 15,298 monocytes from 26 patients, 19,985 T cells from 26 patients, and 8,179 B cells from 23 patients.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                     leukocyte-poor   leukocyte-rich   One-sided            leukocyte-rich
  -------------------------------------------------------------- ----------------------------------------------------------------------------------- ---------------- ---------------- -------------------- ------------------------
                                                                 THY1^**−**^ Cadherin-11^**−**^                                                      21%              4%               1.00                 0.04 (0--0.2)

  Lining (SC-F4)                                                 THY1^**−**^ Cadherin-11^**+**^                                                      18%              2%               1.00                 0.1 (0--0.3)

                                                                 THY1^**−**^ CD34^**+**^ HLA-DR^**hi**^                                              7%               3%               0.87                 0.5 (0.3--1.2)

                                                                 THY1^**−**^ CD34^**−**^ HLA-DR^**hi**^                                              17%              15%              0.48                 1.2 (0.3--4.4)

  *HLA*^**hi**^ sublining (SC-F2)                                **THY1**^**+**^ **CD34**^**−**^ **HLA-DR**^**hi**^                                  **2%**           **36%**          **1.9×10**^**−5**^   **33.8 (11.7--113.1)**

  *DKK3*^**+**^ sublining (SC-F3)                                THY1^**+**^ CD34^**−**^ HLA-DR^**low**^                                             16%              15%              0.66                 0.8 (0.3--1.8)

  *CD34*^**+**^ sublining (SC-F1)                                THY1^**+**^ CD34^**+**^ HLA-DR^**low**^                                             18%              4%               1.00                 0.2 (0.1--0.4)

                                                                 **THY1**^**+**^ **CD34**^**+**^ **HLA-DR**^**hi**^                                  **2%**           **21%**          **1.6×10**^**−4**^   **25.5 (7.5--101.8)**

  *NUPR1*^**+**^ (SC-M2)                                         CD11c^**−**^                                                                        30%              4%               1.00                 0.1 (0--0.4)

  *IL1B*^**+**^ (SC-M1), IFN-activated (SC-M4)                   CD11c^**+**^ CCR2^**+**^                                                            34%              40%              0.23                 1.6 (0.7--3.6)

                                                                 CD11c^**+**^ CD38^**−**^                                                            13%              2%               1.00                 0.1 (0--0.3)

                                                                 CD11c^**+**^ CD38^**−**^ CD64^**+**^                                                13%              3%               0.93                 0.3 (0.1--1)

  *IL1B*^**+**^ (SC-M1), IFN-activated (SC-M4),\                 **CD11c**^**+**^ **CD38**^**+**^                                                    **15%**          **51%**          **6.7×10**^**−5**^   **7.8 (3.6--17.2)**
  C1QA^**+**^ (SC-M3)                                                                                                                                                                                       

                                                                 CD4^**−**^ CD8^**−**^                                                               15%              9%               0.95                 0.6 (0.3--1)

  *CCR7*^**+**^(SC-T1)                                           CD4^**+**^ CCR2^**+**^                                                              26%              13%              1.00                 0.4 (0.2--0.7)

                                                                 CD4^**+**^ HLA-DR^**+**^                                                            6%               2%               0.83                 0.7 (0.2--4.1)

                                                                 CD4^**+**^ PD-1^**+**^ ICOS^**−**^                                                  13%              12%              0.81                 0.9 (0.5--1.6)

  Tph and Tfh (SC-T3)                                            **CD4**^**+**^ **PD-1**^**+**^ **ICOS**^**+**^                                      **11%**          **25%**          **2.7×10**^**−4**^   **3.0 (1.7--5.2)**

                                                                 CD8^**+**^ PD-1^**−**^ HLA-DR^**−**^                                                14%              9%               0.76                 0.7 (0.3--1.5)

  *GZMK*^**+**^*GZMB*^**+**^(SC-T6)*, GZMK*^**+**^ (SC-T4)*,*\   CD8^**+**^ PD-1^**−**^ HLA-DR^**+**^                                                2%               1%               0.64                 0.9 (0.4--2.2)
  CTLs (SC-T5)                                                                                                                                                                                              

                                                                 CD8^**+**^ PD-1^**+**^ HLA-DR^**−**^                                                13%              14%              0.40                 1.1 (0.6--1.9)

  Tph and Tfh (SC-T3)                                            **CD8**^**+**^ **PD-1**^**+**^ **HLA-DR**^**+**^                                    **1%**           **15%**          **9.2×10**^**−5**^   **11.8 (4.9--34.2)**

  plasmablasts (SC-B4)                                           **CD38**^**++**^ **CD20**^**−**^ **IgM**^**−**^ **IgD**^**−**^                      **6%**           **12%**          **0.01**             **3.3 (1.2--10.5)**

                                                                 **CD38**^**++**^ **CD20**^**−**^ **IgM**^**+**^ **HLA-DR**^**+**^                   **1%**           **3%**           **0.01**             **6.9 (1.3--83.1)**

  Memory B cells (SC-B2)                                         IgM^**−**^ IgD^**−**^ HLA-DR^**−**^                                                 27%              2%               1.00                 0.1 (0--0.3)

                                                                 CD38^**+**^ HLA-DR^**++**^ CD20^**−**^ CD11c^**+**^                                 19%              6%               0.56                 0.9 (0.1--6.7)

  ABCs (SC-B3)                                                   **IgM**^**−**^ **IgD**^**−**^ **HLA-DR**^**++**^ **CD20**^**+**^ **CD11c**^**+**^   **4%**           **12%**          **2.7×10**^**−3**^   **5.7 (1.8--22.3)**

                                                                 IgM^**−**^ IgD^**−**^ HLA-DR^**+**^                                                 32%              20%              0.98                 0.4 (0.2--1)

                                                                 IgA^**+**^ IgM^**−**^ IgD^**−**^                                                    5%               4%               0.68                 0.9 (0.5--1.6)

  Naïve B cells (SC-B1)                                          IgM^**+**^ IgD^**−**^                                                               22%              11%              0.97                 0.5 (0.2--1)

                                                                 IgM^**+**^ IgD^**+**^ CD11c^**−**^                                                  12%              26%              0.02                 4.0 (1.3--12.0)

                                                                 IgM^**+**^ IgD^**+**^ CD11c^**+**^                                                  4%               7%               0.14                 2.2 (0.74 -- 7.7)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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